ReviewCell death & disease2025
Gasdermins in neurodegeneration: emerging mechanisms and therapeutic targets.
Review in Cell death & disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Emerging roles of granzymes in neurodegeneration and neuroinflammation: mechanistic insights and therapeutic opportunities.Acta neuropathologica · 2026Review
- Porcine plasma-derived extracellular vesicles orchestrate multi-target neuroimmune reconfiguration to alleviate Alzheimer's disease pathology in a 5×FAD mouse model.Journal of neuroinflammation · 2026Article
- Lysophospholipids in Synucleinopathies: A Conceptual Framework Linking Proteostasis and Neuroinflammatory Signaling.Brain sciences · 2026Review
- The Central Role of Neuronal Cell Death in Alzheimer's Disease Pathobiology.Biomedicines · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Gasdermins (GSDM) are pore-forming proteins that mediate pyroptosis, an inflammatory form of programmed cell death characterized by membrane permeabilization and the release of intracellular contents. Beyond their roles in host defense and immunity, recent studies have revealed critical contributions of GSDMs, particularly GSDMD and GSDME, to the pathogenesis of neurodegenerative disorders. Their functional scope has now expanded beyond executing cell death to roles in tissue regeneration and food tolerance. The recent discovery that intact, full-length GSDMs can form pores is prompting a reevaluation of long-standing models of gasdermin activation. How post-transcriptional modifications (PTMs) regulate this unconventional activity, and under what physiological or pathological contexts these alternative mechanisms are engaged, remains an open question. Moreover, the development of neutralizing biologics that specifically target GSDM pores opens new avenues for therapeutic intervention. In light of these emerging insights, this review will provide a comprehensive and up-to-date overview of recent breakthroughs in GSDM research. We highlight advances in the structural basis of GSDM activation and pore assembly. We also discuss how these mechanisms are involved in the pathogenesis of neurodegenerative diseases and therapeutic strategies based on the emerging small-molecule inhibitors and neutralizing biologics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.